ArticleBritish journal of cancer2008
Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2alpha may signal skeletal muscle atrophy in weight-losing cancer patients.
Article in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03191955 (Biochemical and Functional Biomarkers of Cachexia in Cancer Patients), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biochemical and Functional Biomarkers of Cachexia in Cancer Patients
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Extracellular vesicles derived from tumour cells as a trigger of energy crisis in the skeletal muscle.Journal of cachexia, sarcopenia and muscle · 2022Article
- Article
- Shared and distinct mechanisms of skeletal muscle atrophy: A narrative review.Ageing research reviews · 2021Review
- Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?Journal of cachexia, sarcopenia and muscle · 2020Review
- Cancer Cachexia Induces Preferential Skeletal Muscle Myosin Loss When Combined With Denervation.Frontiers in physiology · 2020Article
- Clinical and biological characterization of skeletal muscle tissue biopsies of surgical cancer patients.Journal of cachexia, sarcopenia and muscle · 2019Article
- L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.Canadian journal of gastroenterology & hepatology · 2019Review
- Imoxin attenuates LPS-induced inflammation and MuRF1 expression in mouse skeletal muscle.Physiological reports · 2018Article
- Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle.Nature medicine · 2018Article
- Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.Hepatology (Baltimore, Md.) · 2017Article
- Linking Cancer Cachexia-Induced Anabolic Resistance to Skeletal Muscle Oxidative Metabolism.Oxidative medicine and cellular longevity · 2017Review
- Gelsolin suppresses gastric cancer metastasis through inhibition of PKR-p38 signaling.Oncotarget · 2016Article
- Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?BMC cancer · 2016Review
- The angiotensin-(1-7)/Mas axis reduces myonuclear apoptosis during recovery from angiotensin II-induced skeletal muscle atrophy in mice.Pflugers Archiv : European journal of physiology · 2015Article
- Discerning primary and secondary factors responsible for clinical fatigue in multisystem diseases.Biology · 2014Review
- Skeletal muscle myofilament adaptations to aging, disease, and disuse and their effects on whole muscle performance in older adult humans.Frontiers in physiology · 2014Review
- Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle.PloS one · 2014Article
- Regulation of muscle protein synthesis and the effects of catabolic states.The international journal of biochemistry & cell biology · 2013Review
- Diaphragm and ventilatory dysfunction during cancer cachexia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics.Journal of applied physiology (Bethesda, Md. : 1985) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies suggest that the activation (autophosphorylation) of dsRNA-dependent protein kinase (PKR) can stimulate protein degradation, and depress protein synthesis in skeletal muscle through phosphorylation of the translation initiation factor 2 (eIF2) on the alpha-subunit. To understand whether these mediators are important in muscle wasting in cancer patients, levels of the phospho forms of PKR and eIF2alpha have been determined in rectus abdominus muscle of weight losing patients with oesophago-gastric cancer, in comparison with healthy controls. Levels of both phospho PKR and phospho eIF2alpha were significantly enhanced in muscle of cancer patients with weight loss irrespective of the amount and there was a linear relationship between phosphorylation of PKR and phosphorylation of eIF2alpha (correlation coefficient 0.76, P=0.005). This suggests that phosphorylation of PKR led to phosphorylation of eIF2alpha. Myosin levels decreased as the weight loss increased, and there was a linear relationship between myosin expression and the extent of phosphorylation of eIF2alpha (correlation coefficient 0.77, P=0.004). These results suggest that phosphorylation of PKR may be an important initiator of muscle wasting in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.